The purpose of this study is to determine the safety and effectiveness of the HeartWare Ventricular Assist System in patients with chronic Stage D/NYHA Class IIIB/IV left ventricular failure who have received and failed optimal medical therapy, and who are ineligible for cardiac transplantation. The HeartWare Ventricular Assist System (VAS) is intended for use in patients with chronic Stage D/NYHA Class IIIB/IV left ventricular failure who have received and failed optimal medical therapy and who are ineligible for cardiac transplantation. Please contact Jessica Cobb at 352.273.7837 or firstname.lastname@example.org.
Endurance Supplemental Trial
This trial studies the stroke incidence in patients implanted with a HeartWare® HVAD who receive optimal blood pressure management. The study compares results of stroke incidence in a new cohort of subjects receiving optimal blood pressure management to a reference stroke incidence observed in the original IDE clinical trial (HW004) that did not specify optimal blood pressure management. Please contact Jessica Cobb at 352.273.7837 or email@example.com.
This trial studies the safety and effectiveness of the HeartMate3 LVAS by demonstrating non-inferiority to the HMII LVAS (HMII) when used for the treatment of advanced, refractory, left ventricular heart failure. The HM3 LVAS is intended to provide hemodynamic support in patients with advanced, refractory left ventricular heart failure; either for short term support, such as a bridge to cardiac transplantation (BTT) or myocardial recovery, or as long-term support, such as destination therapy (DT). The HM3 is intended for use inside or outside the hospital. Please contact Jessica Cobb at 352.273.7837 or firstname.lastname@example.org.
Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on ntpRo-bnp in Patients Stabilized from an Acute Heart Failure Episode
The PIONEER HF research study will compare the effects of an investigational medicine called LCZ696 with those of an approved medicine in reducing the risk of death and rehospitalization in adults who have been hospitalized for acute heart failure.
A Study of Vericiguat in Participants with Heart Failure with Reduced Ejection Fraction
This is a randomized, placebo-controlled study of the effects of an investigational drug called vericiguat (MK-1242) in participants with heart failure with reduced ejection fraction, to investigate whether vericiguat is superior to placebo in increasing the time to first occurrence of cardiovascular death or heart failure hospitalization.
Please contact our Clinical Trials Office for information: (352) 273-8933 email@example.com